PLEASANTON, Calif. , Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025.

Recent Updates

Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million .

Ended the second quarter with cash and cash equivalents and marketable securities of $447.3 million , representing a $20 million increase over the prior quarter.

Entered into a definitive agreement to acquire Scale Biosciences for upfront cash and stock consideration of $30 million , plus contingent consideration that could become payable upon the achievement of certain milestones. The acquisition strengt

See Full Page